DK167815B1 - Antibiotikum a 40926 mannosyl-aglycon og farmaceutisk acceptable additionssalte deraf, fremgangsmaade til fremstilling heraf, anvendelse af forbindelsen til fremstilling af et medikament samt farmaceutisk praeparat indeholdende en saadan forbindelse - Google Patents

Antibiotikum a 40926 mannosyl-aglycon og farmaceutisk acceptable additionssalte deraf, fremgangsmaade til fremstilling heraf, anvendelse af forbindelsen til fremstilling af et medikament samt farmaceutisk praeparat indeholdende en saadan forbindelse Download PDF

Info

Publication number: DK167815B1
Authority: DK; Denmark
Prior art keywords: antibiotic; acid; factor; aqueous; preparing
Prior art date: 1985-12-30

Application number

DK617086A

Other languages

Danish (da)

English (en)

Other versions

DK617086D0 (da

DK617086A (da

Inventor

Giovanni Cassani

Francesco Parenti

Enrico Selva

Beth P Goldstein

Peetro Ferrari

Original Assignee

Lepetit Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-12-30

Filing date

1986-12-19

Publication date

1993-12-20

1986-12-19 Application filed by Lepetit Spa filed Critical Lepetit Spa

1986-12-19 Publication of DK617086D0 publication Critical patent/DK617086D0/da

1987-07-01 Publication of DK617086A publication Critical patent/DK617086A/da

1993-12-20 Application granted granted Critical

1993-12-20 Publication of DK167815B1 publication Critical patent/DK167815B1/da

Links

BEVDFPMXVNOQBI-AXNWEOKVSA-N (19R,22R,34S,37R,40R,52S)-64-[(2S,3R,4R,5S,6S)-3-amino-6-carboxy-4,5-dihydroxyoxan-2-yl]oxy-5,32-dichloro-2,26,31,49-tetrahydroxy-22-(methylamino)-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14(63),15,17(62),23(61),24,26,29(60),30,32,41,43,45(57),46(51),47,49,65-henicosaene-52-carboxylic acid Chemical compound CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)C(O)C7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3cccc(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(O)=O)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3N)C(O)=O)cc4)NC1=O)c2 BEVDFPMXVNOQBI-AXNWEOKVSA-N 0.000 title claims abstract description 74
150000003839 salts Chemical class 0.000 title claims abstract description 34
238000000034 method Methods 0.000 title claims description 28
150000001875 compounds Chemical class 0.000 title claims description 21
239000000825 pharmaceutical preparation Substances 0.000 title description 3
230000003115 biocidal effect Effects 0.000 claims abstract description 27
125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract description 8
238000004519 manufacturing process Methods 0.000 claims abstract description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 20
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 15
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 14
238000006243 chemical reaction Methods 0.000 claims description 14
239000003480 eluent Substances 0.000 claims description 13
230000008569 process Effects 0.000 claims description 12
239000011780 sodium chloride Substances 0.000 claims description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 8
-1 cyclic alkyl ethers Chemical class 0.000 claims description 7
239000003960 organic solvent Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
244000063299 Bacillus subtilis Species 0.000 claims description 6
235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
238000010521 absorption reaction Methods 0.000 claims description 5
230000000845 anti-microbial effect Effects 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 5
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 claims description 5
239000008363 phosphate buffer Substances 0.000 claims description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
229910021204 NaH2 PO4 Inorganic materials 0.000 claims description 4
238000000862 absorption spectrum Methods 0.000 claims description 4
239000003242 anti bacterial agent Substances 0.000 claims description 4
229940088710 antibiotic agent Drugs 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000007062 hydrolysis Effects 0.000 claims description 4
238000006460 hydrolysis reaction Methods 0.000 claims description 4
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
230000002378 acidificating effect Effects 0.000 claims description 3
125000002723 alicyclic group Chemical group 0.000 claims description 3
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
238000010828 elution Methods 0.000 claims description 3
230000001747 exhibiting effect Effects 0.000 claims description 3
229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
230000014759 maintenance of location Effects 0.000 claims description 3
235000010755 mineral Nutrition 0.000 claims description 3
239000011707 mineral Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
238000004007 reversed phase HPLC Methods 0.000 claims description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 claims description 2
UEUIKXVPXLWUDU-UHFFFAOYSA-N 4-diazoniobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C([N+]#N)C=C1 UEUIKXVPXLWUDU-UHFFFAOYSA-N 0.000 claims description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims description 2
125000005360 alkyl sulfoxide group Chemical group 0.000 claims description 2
238000004458 analytical method Methods 0.000 claims description 2
238000012474 bioautography Methods 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000003301 hydrolyzing effect Effects 0.000 claims description 2
238000001819 mass spectrum Methods 0.000 claims description 2
238000010992 reflux Methods 0.000 claims description 2
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 2
229950000244 sulfanilic acid Drugs 0.000 claims description 2
238000005160 1H NMR spectroscopy Methods 0.000 claims 1
MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 claims 1
229910019142 PO4 Inorganic materials 0.000 claims 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims 1
238000001228 spectrum Methods 0.000 claims 1
238000002604 ultrasonography Methods 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 9
244000005700 microbiome Species 0.000 abstract description 7
208000035473 Communicable disease Diseases 0.000 abstract description 3
DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
229910001868 water Inorganic materials 0.000 description 19
239000000243 solution Substances 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
239000007858 starting material Substances 0.000 description 14
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 12
239000002585 base Substances 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
102000003712 Complement factor B Human genes 0.000 description 9
108090000056 Complement factor B Proteins 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
238000000855 fermentation Methods 0.000 description 8
230000004151 fermentation Effects 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
235000014347 soups Nutrition 0.000 description 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000011347 resin Substances 0.000 description 6
229920005989 resin Polymers 0.000 description 6
238000001914 filtration Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
229910021529 ammonia Inorganic materials 0.000 description 4
235000011114 ammonium hydroxide Nutrition 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
238000010533 azeotropic distillation Methods 0.000 description 4
238000004166 bioassay Methods 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
238000010612 desalination reaction Methods 0.000 description 4
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 4
238000000746 purification Methods 0.000 description 4
229910001220 stainless steel Inorganic materials 0.000 description 4
239000010935 stainless steel Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
108010056243 alanylalanine Proteins 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
239000012062 aqueous buffer Substances 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000010255 intramuscular injection Methods 0.000 description 3
239000007927 intramuscular injection Substances 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000606124 Bacteroides fragilis Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000193163 Clostridioides difficile Species 0.000 description 2
206010009657 Clostridium difficile colitis Diseases 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241000204031 Mycoplasma Species 0.000 description 2
208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
206010037128 Pseudomembranous colitis Diseases 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229940047650 haemophilus influenzae Drugs 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
HXBYBCASAVUYKF-JBBNEOJLSA-N (4s,5s,6r,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical group CC(=O)C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO HXBYBCASAVUYKF-JBBNEOJLSA-N 0.000 description 1
YRMCBQLZVBXOSJ-PCFSSPOYSA-N (e)-3-[(6r,6as)-4-hydroxy-6-methoxy-3-methyl-11-oxo-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]prop-2-enamide Chemical compound CO[C@H]1NC2=C(O)C(C)=CC=C2C(=O)N2C=C(\C=C\C(N)=O)C[C@@H]12 YRMCBQLZVBXOSJ-PCFSSPOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
241000187362 Actinomadura Species 0.000 description 1
241000187361 Actinomadura sp. Species 0.000 description 1
TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
101710134784 Agnoprotein Proteins 0.000 description 1
PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
241000193468 Clostridium perfringens Species 0.000 description 1
241000186427 Cutibacterium acnes Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000333125 Nonomuraea gerenzanensis Species 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000186429 Propionibacterium Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
229910021607 Silver chloride Inorganic materials 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000005273 aeration Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000012459 agar diffusion assay Methods 0.000 description 1
238000002814 agar dilution Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
235000019728 animal nutrition Nutrition 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
XDXFALYQLCMAQN-WLHGVMLRSA-N butanedioic acid;(e)-but-2-enedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)\C=C\C(O)=O XDXFALYQLCMAQN-WLHGVMLRSA-N 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012084 conversion product Substances 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
229940073579 ethanolamine hydrochloride Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000006052 feed supplement Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
239000006877 oatmeal agar Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940055019 propionibacterium acne Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/19—Antibiotic
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Compounds Of Unknown Constitution (AREA)

DK617086A 1985-12-30 1986-12-19 Antibiotikum a 40926 mannosyl-aglycon og farmaceutisk acceptable additionssalte deraf, fremgangsmaade til fremstilling heraf, anvendelse af forbindelsen til fremstilling af et medikament samt farmaceutisk praeparat indeholdende en saadan forbindelse DK167815B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB858531846A GB8531846D0 (en)	1985-12-30	1985-12-30	Antibiotic a 40926 mannosyl aglycon
GB8531846		1985-12-30

Publications (3)

Publication Number	Publication Date
DK617086D0 DK617086D0 (da)	1986-12-19
DK617086A DK617086A (da)	1987-07-01
DK167815B1 true DK167815B1 (da)	1993-12-20

Family

ID=10590309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK617086A DK167815B1 (da)	1985-12-30	1986-12-19	Antibiotikum a 40926 mannosyl-aglycon og farmaceutisk acceptable additionssalte deraf, fremgangsmaade til fremstilling heraf, anvendelse af forbindelsen til fremstilling af et medikament samt farmaceutisk praeparat indeholdende en saadan forbindelse

Country Status (14)

Country	Link
US (1)	US4782042A (es)
EP (1)	EP0228015B1 (es)
JP (1)	JP2514942B2 (es)
KR (2)	KR950010460B1 (es)
AT (1)	ATE71113T1 (es)
DE (1)	DE3683266D1 (es)
DK (1)	DK167815B1 (es)
ES (1)	ES2038593T3 (es)
GB (1)	GB8531846D0 (es)
GR (1)	GR3003514T3 (es)
HU (1)	HU201099B (es)
IE (1)	IE59603B1 (es)
IL (1)	IL81105A (es)
ZA (1)	ZA869716B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK363587A (da) *	1986-07-30	1988-01-31	Smithkline Beckman Corp	Antibiotika og fremstilling heraf under anvendelseaf actinomadura parvosata
GB8621912D0 (en) *	1986-09-11	1986-10-15	Lepetit Spa	Increasing ratio of components of anti-biotic complex
GR871488B (en) *	1986-10-10	1987-11-12	Lepetit Spa	New antibiotics
ES2084595T3 (es) *	1988-12-27	1996-05-16	Lepetit Spa	Procedimiento quimico mejorado para preparar el antibiotico l/17392 (desglucoteicoplanina) y sus sales.
US5206834A (en) *	1989-10-14	1993-04-27	Mitsubishi Denki Kabushiki Kaisha	Semiconductor memory device performing last in-first out operation and the method for controlling the same
DK0424051T3 (da) *	1989-10-16	1995-02-27	Lilly Co Eli	Glycopeptid-antibiotika
US5224972A (en) *	1990-09-11	1993-07-06	Frye Gregory C	Coatings with controlled porosity and chemical properties
AU8865191A (en) *	1990-12-05	1992-07-08	Gruppo Lepetit S.P.A.	38-decarboxy-38-hydroxymethyl derivatives of teicoplanin antibiotics, and a process for preparing them
US5606036A (en) *	1991-03-27	1997-02-25	Gruppo Lepetit Spa	Antibiotic A 40926 ester derivatives
CA2099866C (en)	1991-03-27	2002-07-09	Rolf H. Hermann	Antibiotic a 40926 ester derivatives
US5750509A (en) *	1991-07-29	1998-05-12	Gruppo Lepetit S.P.A.	Amide derivatives of antibiotic A 40926
CN1036654C (zh) *	1993-01-01	1997-12-10	格鲁波莱佩蒂特公司	抗菌素a40926的酰氨衍生物及其制备方法
JP4051421B2 (ja) *	1995-07-05	2008-02-27	サノフイ−アベンテイス・エツセ・ピー・アー	等電点電気泳動によるダルバヘプチド抗生物質の精製
DE69708293T2 (de)	1996-04-23	2002-05-02	Biosearch Italia S.P.A., Gerenzano	Chemisches Verfahren zur Herstellung von Amidderivaten von A 40926 Antibiotikum
HUE041133T2 (hu) *	2002-11-18	2019-05-28	Vicuron Pharmaceuticals Llc	Dalbavancin adagolási módszer bakteriális fertõzések kezelésére
US20060074014A1 (en)	2002-11-18	2006-04-06	Vicuron Pharmaceuticals Inc.	Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) *	2002-11-18	2006-10-10	Vicuron Pharmaceuticals, Inc.	Dalbavancin compositions for treatment of bacterial infections
JP5852880B2 (ja) *	2011-12-28	2016-02-03	国立研究開発法人国立循環器病研究センター	温度感応性材料
US20220204551A1 (en) *	2019-04-30	2022-06-30	Huvepharma Italia S.R.L.	Method for the purification of lipoglycopeptide antibiotics
KR102467772B1 (ko)	2022-08-23	2022-11-16	최세근	디자인에 따라 결합 가능한 모듈이 구비된 신발

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4521335A (en) *	1983-07-13	1985-06-04	Smithkline Beckman Corporation	Aglycone and pseudo-aglycones of the AAD 216 antibiotics
GB8425685D0 (en) *	1984-10-11	1984-11-14	Lepetit Spa	Antibiotic a 40926 complex

1985
- 1985-12-30 GB GB858531846A patent/GB8531846D0/en active Pending
1986
- 1986-12-15 EP EP86117453A patent/EP0228015B1/en not_active Expired - Lifetime
- 1986-12-15 AT AT86117453T patent/ATE71113T1/de not_active IP Right Cessation
- 1986-12-15 ES ES198686117453T patent/ES2038593T3/es not_active Expired - Lifetime
- 1986-12-15 DE DE8686117453T patent/DE3683266D1/de not_active Expired - Lifetime
- 1986-12-19 DK DK617086A patent/DK167815B1/da not_active IP Right Cessation
- 1986-12-23 IE IE338186A patent/IE59603B1/en not_active IP Right Cessation
- 1986-12-23 US US06/945,732 patent/US4782042A/en not_active Expired - Fee Related
- 1986-12-26 IL IL81105A patent/IL81105A/xx not_active IP Right Cessation
- 1986-12-29 ZA ZA869716A patent/ZA869716B/xx unknown
- 1986-12-29 HU HU865503A patent/HU201099B/hu not_active IP Right Cessation
- 1986-12-29 JP JP61315964A patent/JP2514942B2/ja not_active Expired - Lifetime
- 1986-12-29 KR KR1019860011487A patent/KR950010460B1/ko not_active Expired - Fee Related
1987
- 1987-07-01 KR KR1019870006803A patent/KR960010556B1/ko not_active Expired - Fee Related
1992
- 1992-01-03 GR GR910402184T patent/GR3003514T3/el unknown

Also Published As

Publication number	Publication date
IE863381L (en)	1987-06-30
KR870006193A (ko)	1987-07-09
GB8531846D0 (en)	1986-02-05
JPS62175499A (ja)	1987-08-01
KR950010460B1 (ko)	1995-09-18
KR890002230A (ko)	1989-04-08
IE59603B1 (en)	1994-03-09
HU201099B (en)	1990-09-28
EP0228015A2 (en)	1987-07-08
JP2514942B2 (ja)	1996-07-10
US4782042A (en)	1988-11-01
EP0228015B1 (en)	1992-01-02
ES2038593T3 (es)	1993-08-01
DK617086D0 (da)	1986-12-19
KR960010556B1 (ko)	1996-08-02
EP0228015A3 (en)	1987-12-16
ATE71113T1 (de)	1992-01-15
ZA869716B (en)	1987-10-28
DE3683266D1 (de)	1992-02-13
HUT43091A (en)	1987-09-28
GR3003514T3 (es)	1993-03-16
DK617086A (da)	1987-07-01
IL81105A0 (en)	1987-03-31
IL81105A (en)	1991-09-16

Publication	Publication Date	Title
DK167815B1 (da)	1993-12-20	Antibiotikum a 40926 mannosyl-aglycon og farmaceutisk acceptable additionssalte deraf, fremgangsmaade til fremstilling heraf, anvendelse af forbindelsen til fremstilling af et medikament samt farmaceutisk praeparat indeholdende en saadan forbindelse
EP0177882B1 (en)	1990-01-03	Antibiotic a 40926 complex and its pure factors pa, pb, a, b and bo
KR960010557B1 (ko)	1996-08-02	항생물질 a 40926 n-아실아미노글루쿠로닐 아글리콘 및 항생물질 a 40926 아글리콘
EP0327548B1 (en)	1992-07-22	Glycopeptide antibiotics
JPH0819155B2 (ja)	1996-02-28	脱マンノシルテイコプラニン誘導体
US5322777A (en)	1994-06-21	Antibiotic GE 2270
CA2037779C (en)	2002-11-05	Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
US4908351A (en)	1990-03-13	Antibiotic a 42867 derivative
EP0254999B1 (en)	1992-09-23	Antibiotic a 42867 and the addition salts thereof
JP2997480B2 (ja)	2000-01-11	抗生物質ｇｅ２２７０
CA2038667C (en)	2002-09-17	Process for the preparation of mannosyl teicoplanin derivatives and mannosyl teicoplanin aglycone
JP4452505B2 (ja)	2010-04-21	抗生物質ｇｅ８１１１２ファクターａ、ｂ、ｂ１、その製薬学的に許容され得る塩および組成物および使用

Legal Events

Date	Code	Title	Description
1993-12-20	B1	Patent granted (law 1993)
1999-04-19	PBP	Patent lapsed